



Nexus AG: VERY STRONG SALES AND EARNINGS INCREASE IN THE FIRST HALF-YEAR 2021

Donaueschingen, 05 August 2021: Nexus AG, one of the leading European suppliers of software solutions in the healthcare sector, was able to increase its sales by 17% and EBIT by approx. 20% in the first six months of 2021. As a result, the continually positive development of sales and earnings of the last years could be continued.

Sales improved from KEUR 77,659 to KEUR 90,857 (+17.0%) in the first half-year 2021. The international share of total business volume was 46.6% (6M 2020: 44.1%) and amounted to KEUR 42,320 compared to KEUR 34,267 (6M-2020).

The consolidated surplus rose very sharply by 22.2% to KEUR 7,580 (6M 2020: KEUR 6,201), and consolidated earnings before interest and taxes (EBIT) rose by 19.9% to KEUR 10,147 (6M 2020: KEUR 8,462); EBITA increased by 18.8% from KEUR 10,375 (6M-2020) to KEUR 12,329, and EBITDA increased by 10.4% to KEUR 18,391 (6M 2020: KEUR 16,663).



Operating cash flow increased by 3.8% to KEUR 27,070 in the first six months (6M-2020: KEUR 26,081) and remains at a very high level. As of 30/06/2021, the company had cash resources at its disposal in the amount of KEUR 29,553 (31/12/2020: KEUR 28,177). Nexus AG had equity capital amounting to KEUR 128,800 as of 30/06/2021 (31/12/2020: KEUR 123,583). Consequently, the equity capital rate is 50.9% (31/12/2020: 55.4%). This demonstrates that Nexus AG has a sustainable and healthy balance sheet as well as sufficient capital for further financing of its European growth strategy.

The detailed half-year report can be found on our homepage at:
<https://en-en.nexus-ag.de/company/investor-relations/financial-reports>

About Nexus AG

Nexus AG develops and sells software solutions for the international healthcare market. With our core Hospital Information System (NEXUS / HIS) and integrated diagnostic modules (NEXUS / DIS), we have a unique product range, which can cover almost all functional requirements of hospitals, psychiatric institutions, rehabilitation facilities and diagnostic centers within our own product families. The focus of product development is on easy-to-use process support that increases efficiency and safety in patient treatment. NEXUS employs approx. 1,500 people, is present in seven European countries with its own sites and serves customers in an additional 23 countries via certified dealers. Thanks to continuously growing demand for NEXUS products, we have been able to build up a large customer base in recent years and regularly show increases in sales and results.